Obesity - orlistat (replaced by CG43)
Orlistat for the treatment of obesity in adults
Summary
This guidance is obsolete and has been replaced by CG43 Obesity. Orlistat must be viewed as only one of a number of approaches in tackling obesity Nice has recommended that: Orlistat should be only be prescribed for people who have lost at least 2.5 kg in weight by diet and exercise in the mo ...
Guidance documents
Implementing this guidance
We will consult on our review plans for this guidance in February 2004
About this guidance
Technology appraisals TA22
Issued: March 2001